The results demonstrate that Albuferon (albumin-interferon alpha 2b) in combination with ribavirin was safe, well tolerated and showed robust antiviral activity. The data were presented at the 41st annual meeting of the European association for the study of the liver (EASL).
“We believe that an interferon with less frequent dosing than pegylated interferon, and with comparable safety and efficacy, would be an important therapeutic option for patients with chronic hepatitis C. Albuferon appears capable of meeting this target at doses of 900-1200 mcg at two-week intervals,” commented Dr David Stump, executive vice president of drug development at Human Genome Sciences.